Business activity cleared — no excluded categories detected
Source: stored filing inputs · Balance sheet as of 2026-06-30 · Income statement as of 2025-12-31
AbCellera Biologics Inc. (ABCL) is currently considered not halal (non-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Research only, not the primary verdict above — computed from SEC EDGAR filings and business-activity classification, same as the Discord bot's !halal command.
Business activity: cleared (no excluded categories detected)
Source: stored filing inputs · Balance sheet as of 2026-06-30 · Income statement as of 2025-12-31
Combined verdict: AAOIFI Non Compliant Usmani Non Compliant Dow Jones Islamic Non Compliant S&P Shariah Non Compliant MSCI Islamic Non Compliant MSCI Islamic M Non Compliant FTSE Shariah Non Compliant
ℹ️ AAOIFI, Usmani, Dow Jones Islamic, S&P Shariah, MSCI Islamic, MSCI Islamic M, FTSE Shariah screen this company as Non-Compliant on the financial ratios alone — a ratio failure is decisive on its own, so those verdicts stand regardless of what the business-activity screen concluded.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 51.00 | NEUTRAL |
| Stochastic %K (14) | 1.85 | BUY |
| CCI (20) | -140.24 | BUY |
| Williams %R (14) | -98.15 | BUY |
| MACD (12,26,9) | -0.29 | SELL |
| ROC (10) | -14.54 | SELL |
| Momentum (10) | -1.78 | SELL |
| EMA (10) | 11.19 | SELL |
| SMA (10) | 11.38 | SELL |
| EMA (20) | 10.79 | SELL |
| SMA (20) | 11.44 | SELL |
| EMA (30) | 10.18 | BUY |
| SMA (30) | 10.03 | BUY |
| EMA (50) | 9.15 | BUY |
| SMA (50) | 8.61 | BUY |
| EMA (100) | 7.58 | BUY |
| SMA (100) | 6.90 | BUY |
| EMA (200) | 6.15 | BUY |
| SMA (200) | 5.25 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 43 |
| ⏰ 4H | BEARISH | 70 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.